Postdoctoral Training Fellow CR-UK Therapeutic Catalyst Grant (Prof T Rabbitts) (ID575) Sutton, London, England
Job description
Key Information
Starting Salary: Future progression is based on annual performance review. If the candidate has not yet been awarded their PhD, the starting salary will be at £34,344 until the successful completion of their viva.
Job Details
The project is focussed on developing chemical compounds that were derived using an intracellular antibody that binds to the T cell acute leukaemia oncogenic transcription factor, LMO2. The first generation Antibody-derived (Abd) compounds have been identified and made into Proteolysis-targeting chimaeras (PROTAC) compounds. The work of this PDTF post will be to develop protocols for successful production of soluble, recombinant LMO2 protein to facilitate structural studies with the compounds. This will involve X-ray crystallography, NMR and other biophysical methods of studying the proteincompound complex for structure-based drug design. New generations of compounds will be synthesised by our collaborating chemistry laboratory.
You should possess a PhD in structural biology and have experience in working with recombinant proteins, in particular antibodies and transcription factors. You must also have track record with protein engineering and as well as in biophysical methods such as X-ray crystallography. Experience with cell-based models, such as 3-D cultures would be an advantage.
The ICR has a workforce agreement stating that Postdoctoral Training Fellows can only be employed for up to 7 years as PDTF at the ICR, providing total postdoctoral experience (including previous employment at this level elsewhere) does not exceed 10 years.
Division Information:
Professor Terry Rabbitts’ research is focused on new strategies using intracellular antibodies and derivates for therapy aimed at hard-to-drug chromosomal translocation gene products. This includes intracellular antibodies for inhibiting transcription factors and protein-protein interactions. The approach has resulted in compounds that bind to the chromosomal translocation LMO2 transcription factor and effect T cell leukaemia cell growth. The aim is to develop these compounds into drugs for refractory T-cell acute leukaemias.
Our approach is multi-disciplinary, integrating molecular biology, cell biology, antibody design, structural biology, and chemical biology. We aim to develop these LMO2 binding compounds to pre-clinical efficacy in this next round to structure-based drug evolution. These will be the first compounds to be derived from an intracellular antibody binding site that have progressed towards phase I clinical trials. The post should lead to further work in the group to drug using intracellular antibody approach.
We encourage all applicants to access the job pack attached for more detailed information regarding this role. You may contact Prof. Terry Rabbitts for further information by emailing [email protected].
About The Institute of Cancer Research
Why work for us?
As a member of staff, you'll have exclusive access to a range of staff benefits.
The ICR is committed to supporting overseas applicants applying for roles, please click here to find out further information.
The Institute of Cancer Research, London, is one of the world's most influential cancer research institutes, with an outstanding record of achievement dating back more than 100 years. Further information about working at the ICR can be found here.
We look forward to receiving applications from all candidates, wherever in the world they are currently based. We will select those who display the potential to become, or to support, the world leading cancer researchers of the future based on their application and performance at interview. However, we particularly welcome British applicants from black and ethnic minority backgrounds, as they are under-represented within the ICR and nationwide in STEM roles.
